NeoDynamics receives first German order of pulse biopsy system NeoNavia

Report this content

NeoDynamics AB (Spotlight Stock Market: NEOD), a MedTech company dedicated to advancing diagnosis and care of breast cancer, today announced that the company has received the first German commercial order of its pulse biopsy system NeoNavia from Hermann-Josef-Hospital in Erkelenz, a teaching hospital of the University of Aachen, a reputed and certified breast centre.

The breast centre at Hermann-Josef-Hospital in Erkelenz with Dr. Uwe Peisker as lead, has accepted to become a reference centre for the introduction of NeoNavia in Germany. As an investigator in the German PULSE-trial* Dr Peisker has already acquired know-how and familiarity with pulse biopsy in diagnosis of breast cancer.

“I have gained significant experience of the new pulse technology through the PULSE trial, and I look forward to act as a reference centre when NeoNavia is introduced in Germany. The innovative pulse biopsy system has a potential to improve clinical practice in all ultrasound guided biopsies, including vacuum biopsy,” says Dr Uwe Peisker from Hermann-Josef-Hospital in Erkelenz.

NeoDynamics’ team in Germany has successfully introduced the pulse biopsy system NeoNavia to physicians at selected clinics, despite the difficulties to access hospitals and medical staff during the pandemic.

“The first commercial order of NeoNavia in Germany is an important milestone for NeoDynamics. I am thrilled that the new pulse technology is embraced by leading physicians, and that they recognize the value it may bring to patients, says Renate Reiss, Country Manager Germany, NeoDynamics.

* The PULSE study is a German multicentre study for the evaluation of NeoNavia in axillary lymph nodes that has completed patient recruitment and is now in the follow-up stage. The first results are expected to be presented in the autumn of 2021.

Anna Eriksrud, CEO,  +46 (0) 708 444 966,
Kai-Uwe Schässburger, Director Clinical Development & Medical Affairs, +49 (0)151 688 092 41 or + 46 (0)762 386 153,

Breast cancer in Germany
Breast cancer is by far the most common cancer and cancer-related cause of death in women in Germany. The annual incidence is approximately 75,000. In addition, more than 6,000 women were diagnosed with an in-situ breast tumour every year. About one in eight women is expected to develop breast cancer over the course of a lifetime. Almost three out of ten affected women are below 55 years of age at diagnosis. It is critical that new biopsy technologies can offer a controlled way for lesion targeting as well as accurate and reliable diagnosis through high quality tissue samples.

About NeoDynamics
NeoDynamics AB (publ) is a Swedish Medical Technology Company dedicated to advancing diagnosis and care of breast cancer. The company has developed an innovative biopsy system, NeoNavia. The pulse biopsy system is built on a patented pulse technology, based on research at the Karolinska Institutet in Sweden. The system is designed to offer clinicians and patients accurate lesion targeting and high tissue yield for correct diagnosis and individualized treatment. NeoNavia is evaluated at leading clinics in UK, Germany and Sweden.

About NeoNavia
NeoNavia is a modern biopsy system with an innovative patented pulse technology intended to be used under ultrasound guidance. It consists of a base unit, a handheld driver and three different types of biopsy needles. Each needle type is driven by the pulse technology providing a more controlled needle insertion and precise placement of the needle in the tumour, enabling high-quality tissue samples from both breasts and lymph nodes. The system is designed to offer accurate lesion targeting and high tissue yield for correct diagnosis and individualized treatment.